DHAP (chemotherapy) explained
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.
[R]-DHAP regimen consists of:
- Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
- (D)examethasone, a glucocorticoid hormone
- (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
- (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.
Dosing regimen
| Drug | Dose | Mode | Days |
|---|
| 375 mg/m2 | IV infusion | Day 0 |
| 40 mg | PO qd | Days 1-4 |
| 2000 mg/m2 | IV infusion over 2 hrs | Day 2, every 12 hours |
| 100 mg/m2 | IV infusion over 24 hrs | Day 1 |
|
Notes and References
- http://www.bloodjournal.org/content/71/1/117.abstract?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&volume=71&firstpage=117&resourcetype=HWCIT&sso-checked=true Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
